Megan Lerner to Case-Control Studies
This is a "connection" page, showing publications Megan Lerner has written about Case-Control Studies.
Connection Strength
0.181
-
Serum discrimination and phenotype assessment of coronary artery disease patents with and without type 2 diabetes prior to coronary artery bypass graft surgery. PLoS One. 2020; 15(8):e0234539.
Score: 0.038
-
Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Invest. 2017 Oct 21; 35(9):573-585.
Score: 0.031
-
The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer's disease. Histochem Cell Biol. 2015 Oct; 144(4):293-308.
Score: 0.027
-
Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2. BMC Genet. 2013 Apr 23; 14:28.
Score: 0.023
-
Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas. 2012 Apr; 41(3):474-80.
Score: 0.021
-
Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
Score: 0.021
-
Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling. Cancer Invest. 2012 Feb; 30(2):180-8.
Score: 0.021